[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563603":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":46,"collaborators":48,"id":51,"slug":20,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":20,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":20,"enrollmentInfo":59,"targetDuration":20,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":20,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Beijing GoBroad Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"JCXH-213 experimental group","EXPERIMENTAL","4 dose groups will be set in this part, following the dose escalation pattern (accelerated titration combined with a \"3 + 3\").",[13],"Drug: JCXH-213,an mRNA-LNP based in vivo CAR therapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","JCXH-213,an mRNA-LNP based in vivo CAR therapy","JCXH-213 infusion",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Kai Hu, Chief Physician","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Kai Hu","CONTACT","+86 15810245863","HK13610956245@163.com",[32],{"facility":33,"status":34,"city":35,"state":20,"zip":20,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Department of Lymphoma and Myeloma, Yuhengnan Road, Changping District, Beijing","RECRUITING","Beijing","China",{"type":38,"coordinates":39},"Point",[40,41],116.39723,39.9075,{"lat":41,"lon":40},[44],{"name":45,"role":28,"phone":20,"phoneExt":20,"email":20},"Kai Hu, doctor",{"type":24,"investigatorFullName":27,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Chief physician",[49],{"name":50,"class":6},"Ruijin Hospital","100563603",false,"NCT06618313","One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r\u002Fr B-NHL","Open-label, Single-arm，Exploratory Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With Relapsed\u002FRefractory B-cell Non-Hodgkin Lymphoma","Inclusion Criteria:\n\n* Cytologically or histopathologically confirmed CD19-positive B-cell Hodgkin lymphoma according to WHO 2022 criteria, including but not limited to pathologically confirmed (1) diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS); (2) follicular lymphoma (FL); (3)histologically transformed into diffuse large B-cell lymphoma; (4) primary mediastinal large B-cell lymphoma (PMBCL); (5) High-grade B-cell lymphoma (HGBCL) etc.\n* ECOG performance status 0 to 1.\n* Existing measurable lesions (Lugano 2014 criteria, as detailed in Appendix 2), meeting one of the following conditions: 1) nodal lesions with a long axis length exceeding 15 mm (short axis length is measurable); 2) extra-nodal lesions with both long axis and short axis lengths exceeding 10 mm.\n\nExclusion Criteria:\n\n* Patients with other malignant tumors within 5 years before screening, except for adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local radical prostatectomy, radical ductal carcinoma in situ, and radical thyroidectomy.\n* B-cell non-Hodgkin lymphoma with active primary or secondary central nervous system involvement.\n* Life expectancy less than 3 months.","ALL","18 Years",{"count":60,"type":61},8,"ESTIMATED","INTERVENTIONAL",[64],"NA","Evaluate the Safety and Efficacy of JCXH-213 in Patients with Relapsed\u002FRefractory B-cell non-Hodgkin Lymphoma",[67,68],"B-Cell Non-Hodgkin Lymphoma-Recurrent","B-Cell Non-Hodgkin Lymphoma-Refractory","2025-05-29",{"date":71,"type":72},"2025-06-03","ACTUAL",{"date":74,"type":72},"2025-03-27",{"date":76,"type":61},"2026-12",{"name":5,"class":6},1]